Amgen Inc.
AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell counā¦ read more
Healthcare
Drug ManufacturersāGeneral
42 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$336.29
Price+2.03%
$6.70
1Y
Price
Market Cap
$181.498b
Large
Price/Earnings 3y Avg5y Avg
23.4x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+31.8%
EBITDA Margin+21.1%
Net Profit Margin+17.1%
Free Cash Flow Margin+31.8%
EBITDA Margin+21.1%
Net Profit Margin+17.1%
Free Cash Flow MarginRevenue
$37.238b
+1.4%
1y CAGR+10.0%
3y CAGR+9.2%
5y CAGREarnings
$7.800b
+1.2%
1y CAGR+16.9%
3y CAGR+13.3%
5y CAGREPS
$14.37
+1.0%
1y CAGR+16.6%
3y CAGR+13.2%
5y CAGRBook Value
$9.190b
$92.504b
Assets$83.314b
Liabilities$57.323b
DebtDebt to Assets
62.0%
3.3x
Debt to EBITDAFree Cash Flow
$8.597b
+6.1%
1y CAGR+8.4%
3y CAGR+2.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company